1. Although previous studies suggest that the renal vasoconstrictor effects of angiotensin I1 (ANG 11) are normally confined to the efferent arterioles, the mechanisms that prevent ANG I1 from constricting preglomerular vessels are still unclear. In the present study, the role of prostaglandins (PG) in protecting preglomerular vessels from ANG I1 constriction was examined in dogs with normal or nonfiltering kidneys in which ANG I1 formation was blocked with captopril and renal artery pressure was servo-controlled at 75-80 mmHg.
Introduction
Although the principal site at which angiytensin I1 (ANG 11) regulates renal vascular resistance is still somewhat controversial [ 11, previous studies from our laboratory [2-51 and other laboratories suggested that ANG I1 acts primarily on the efferent arterioles during physiological acti'vation of the renin-angiotensin system. Infusion of exogenous ANG I1 may cause constriction of preglomerular vessels under certain experimental conditions [ 1, 9] , but these changes appear to be due to activation of various autoregulatory mechanisms since they ' do not occur when renal perfusion pressure is held. constant and changes in tubuloglomerular feedback are prevented [8, lo] . In addition, ANG I1 does not constrict isolated afferent arterioles or interlobular arteries [ 111. Thus considerable evidence suggests that the direct renal vasoconstrictor effects of ANG I1 are localized mainly in the efferent arterioles [9, The selective constrictor action of ANG 1 1 on efferent arterioles is important, because it allows the renin-angiotensin system to help prevent reductions in glomerular hydrostatic pressure and glomerular filtration rate (GFR) in various physiological and pathophysiological conditions such as sodium deprivation, renal artery constriction or increased renal nerve activity [9, 121 . However, the exact mechanisms that protect preglomerular vessels from ANG I1 constriction are not well understood and could be related either to a relative paucity of receptors in these vessels or to release of local vasodilators that selectively protect the afferent arterioles from ANG I1 vasoconstriction. One possible protective mechanism is increased formation of renal prostaglandins (PG) since ANG I1 stimulates PG formation [ 131 and since several of the PG (particularly PGE,, PGD, and PGI,) cause renal vasodilatation [ 141. However, the quantitative importance of the renal PG in protecting preglomerular vessels from ANG I1 constriction and in stabilizing GFR is still unclear. In many of the studies in which interactioes between PG and ANG I1 have been examined, GFR has not been measured. Also, the direct renal effects of ANG 11-PG interactions on the determinants of GFR have often not been separated from possible indirect effects due to changes in renal perfusion pressure and subsequent changes in myogenic activity, or alterations in tubuloglomerular feedback.
The aim of the present study was to examine the possible role of renal -PG in preventing reductions in GFR and in protecting preglomerular vessels from ANG I1 vasoconstriction. This was done by comparing the renal haemodynamic and GFR responses to ANG I1 in control dogs with the responses observed after injection of meclofenamate, an inhibitor of PG synthesis. To examine the role of intrinsic autoregulatory mechanisms in modifyin'g the renal haemodynamic responses to ANG I1 and PG inhibition, experiments were also conducted in non-filtering kidneys in which changes in tubuloglomerular feedback were blocked before and after meclofenamate infusion. Changes in endogenous ANG I1 formation during ANG I1 infusion were also prevented by blocking ANG I1 formation with the converting enzyme inhibitor SQ-14225 (captopril) and renal perfusion pressure was held constant throughout the experiments.
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Methods
Experiments were conducted in male or female greyhounds maintained on a normal sodium diet.
The dogs were anaesthetized with an initial dose of 30 mg of sodium pentobarbital/kg and approximately 5 mg of pentobarbital h-' kg-I was infused intravenously to maintain a relatively constant level of anaesthesia throughout the experiment. Rectal temperature was maintained constant by warming the table on which the dog rested.
The left kidney was exposed through a retroperitoneal flank incision and small sections of the abdominal aorta, renal artery, gonadal vein and ureter were isolated. A catheter was advanced into the renal vein via the gonadal vein for collection of renal venous blood samples. The ureter was cannulated with polyvinyl chloride tubing connected to a T-tube, with one end of the tube attached to a Statham pressure transducer and the other end passing through a photoelectric drop counter for continuous measurement of urine flow rate. Renal blood flow (Rl3F) was measured using an electromagnetic flow transducer connected to a squarewave flowmeter (Carolina Medical Electronics). Renal artery pressure was measured from the catheter inserted into the femoral artery and advanced into the abdominal aorta just below the left renal artery. Mean systemic arterial pressure was measured and systemic arterial blood samples were collected from a catheter inserted into the femoral artery and advanced into the upper aorta above the renal arteries. Mean systemic and renal artery pressures, RBF, urine flow rate and ureteral pressure were recorded continuously on a Grass polygraph (model 7D).
GFR was determined from the renal arteriovenous extraction of [1251]iothalamate (Glofil, Isotex Diagnostics, Friendwood, Texas, 9.S.A.) and calculated as: G F R = ( l -PCVXRBFX[(A-V)/A, where PCV is the systemic arterial packed cell volume measured by the microcapillary method and A and V are the systemic arterial and renal venous lZ5I radioactivities, respectively. Plasma protein concentration was measured with a refractometer (American Optical).
Experimental protocol
ANG II infusion before and afer medofenamate with constant renal artery pressure in normal kidneys. After recovery from surgery, the angiotensin converting enzyme inhibitor SQ-14225 (captopril) was infused intravenously at a rate of 20 pg min-l kg-l after a bolus intravenous injection of 1 mg/kg in order to block endogenous ANG I1 formation throughout the experiment. Previous studies in our laboratory have shown that captopril infusion at a rate of 14 pg min-l kg-' effectively blocks the renal haemodynamic and blood pressure responses to injections of angiotensin I [15] . Sodium chloride solution (154 mmol/l NaC1:saline) was infused intravenously at a rate of 2.0 ml/min throughout the experiment to replace urinary losses. Renal artery pressure was reduced to and maintained at 75-80 mmHg with a servo-controlled silastic occluder [16] and 30-60 min was allowed to stabilize all variables. Renal artery pressure was maintained at the lower limits of autoregulation in order to minimize potential secondary autoregulatory changes in renal resistances that could occur during ANG I1 infusion. Then control measurements were made over the next 10-15 rnin and renal venous and arterial blood samples were obtained for measurements of lz5I radioactivity as well as for plasma protein concentration and PCV. Intravenous ANG I1 infusion was then begun at a rate of 10 ng rnin-' kg-' and continued for 20 min while renal perfusion pressure was maintained constant. Renal venous and systemic arterial blood samples were obtained after 10 and 20 min of ANG I1 infusion for measurements of Iz5I radioactivities, plasma protein concentration and PCV.
Then the rate of ANG II infusion was increased to 20 ng min-' kg-l and continued for 20 min while renal artery pressure was held constant and renal venous and systemic arterial blood samples were obtained after 10 and 20 min of infusion.
After stopping ANG I1 infusion, 60-90 rnin was allowed for all parameters to stabilize and then a bolus injection (5 mg/kg) of the prostaglandin synthetase inhibitor meclofenamate was administered intravenously. Studies by other investigators have demonstrated that doses of meclofenamate even lower than this effectively suppress PG synthesis [17] . Fifteen minutes were allowed and control measurements were made over the next 10-15 min. ANG I1 infusion was then begun at a rate of 10 ng min-l kg-' and continued for 20 min before the infusion rate was increased to 20 ng min-l kg-l, according to the protocol described above. Measurements were made at the same time intervals as in the first part of the experiment.
Glomerular hydrostatic pressure, preglomerular resistance and efferent arteriolar resistance in normal kidneys were calculated according to methods previously described in detail [lo] .
ANG II infi*sion before and after meclofenamate with constant renal artery pressure in non-filtering kidneys. After recovery from surgery, seven dogs were infused with SQ-14225 (1 mg/kg as a bolus injection) followed by a constant infusion of 20 ,ug formation. Then a priming dose of 200-300 ml of mannitol solution (5.4% in saline) was administered intravenously, followed by sustaining infusion of 2.0 ml/min. Renal artery perfusion pressure was reduced to and maintained at 75-80 mmHg with min-' k g -I in order to block endogenous ANG II the servo-controlled silastic occluder and after 10-15 rnin of mannitol infusion and established diuresis, the ureteral outflow catheter was clamped and ureteral pressure was allowed to stabilize for at least 30 min. Renal artery pressure was lowered to 75-80 mmHg in these experiments, since previous studies suggest that glomerular hydrostatic pressure is maintained near normal levels during ureteral occlusion only when renal artery pressure is reduced to the lower limits of renal autoregulation.
After infused intravenously at a rate of 10 ng min-' kg-' while renal perfusion was maintained constant with the servo-controlled silastic occluder. Arterial blood samples for measurements of plasma protein concentration and PCV were obtained at 5, 10, 15 and 20 min after beginning ANG I1 infusion. The rate of ANG I1 infusion was then increased to 20 ng min-l kg-I while renal artery pressure was maintained constant and RBF, ureteral pressure and mean arterial pressure was measured continuously for 20 rnin with arterial blood samples taken at 5, 10, 15 and 20 rnin of ANG I1 infusion at 20 ng and a 30-60 rnin recovery period was allowed before post-control measurements were obtained. After post-control measurements, the ureteral clamp was released in order to reduce any build up of pressure in the kidney caused by ANG I1 infusion and to wash out possible accumulated metabolites. Another new bolus infusion of 200 ml of mannitol was given along with a continuous infusion as describd above. The ureter was again clamped and 30 min was allowed for stabilization. Then a bolus of meclofenamate (5 mg/kg) was injected intravenously and 15 min was allowed before control measurements were made 5-10 rnin apart. ANG I1 was infused at 10 and 20 ng min-' kg-l and the same protocol as described above was followed.
Glomerular hydrostatic and renal segmental resistances in non-filtering kidneys were calculated as previously described [lo].
min-' k g -1 . Then ANG I1 infusion was terminated
Statistical analysis
Data were converted to percentage change from control and analysed via a randomized block factorial analysis of variance. Presence or absence of meclofenamate, ANG I1 dose level and time served as the independent variables in the analysis. In cases where the assumption of homogeneity among variances in the variance-covariance matrix were violated, a three-step testing strategy recommended by Kirk [18] was used. The F values were then evaluated under both the Geisser-Greenhouse and Huynh-Feldt adjustments for degrees of freedom [18] . All analyses of variance and tests of simple main effects were analysed via the BMDF4V general univariate and multivariate analysis of variance program [ 191. Scheffe's procedure was used to evaluate multiple comparisons among treatment means [19] . Observed F values and t values were considered statistically significant only if P < 0.05. Results are expressed as means f SE. (Fig. 2) . Calculated glomerular hydrostatic pressure did not change significantly during ANG I1 infusion.
Results
Effects of A N G II
Effects of ANG II on renal haemodynamics after meclofenamate treatment in normal kidneys maintained at constant perfusion pressure
After injection of meclofenamate, ANG I1 infusion for 20 min at 10 and 20 ng min-l kg-l raised mean arterial blood pressure by 19 and 27 mmHg, respectively, while renal artery pressure was maintained constant at 77 k 1 mmHg. RBF decreased from 2 8 4 f 3 7 to 1 4 1 f 2 3 and 1 2 3 f 2 4 ml/min (Fig. 2) . Calculated glomerular hydrostatic pressure decreased from 58.3 f 2.9 to 53.3f3.4 and 49.0f 1.4 mmHg during ANG I1 infusion at 10 and 20 ng min-l kg-l. The decreases in GFR and glomerular hydrostatic pressure and the increases in preglomerular resistance during ANG I1 infusion were significantly greater after meclofenamate than under control conditions. 
Effects of ANG II on renal haernodynamics in nonfiltering kidneys maintained at constant perfusion pressure
Effects of ANG II on renal haemodynamics after meclofenamate 'treatment in non-filtering kidneys maintained at constant perfusion pressure
After meclofenarnate treatment in non-filtering kidneys ANG I1 infusion at 10 and 20 ng min-' kg-' raised mean arterial blood pressure by 13 and 15 mmHg while decreasing RBF from 13 1 k 8 ml/min to 95 + 8 and 77 f 7 ml/min, respectively (Fig. 3) . In contrast to the effects of ANG I1 before meclofenarnate treatment, ureteral stop-flow pressure and calculated glomerular hydrostatic pressure did not change appreciably after 20 min infusion of ANG 11 at 10 and 20 ng min-l kg-l after injection of 
Discussion
The results from this study suggest that PG may play an important role in preventing reductions in GFR when circulating levels of ANG I1 are increased. This protective effect of PG appears to be due mainly to an interaction of PG and ANG I1 on preglomerular vessels, since meclofenamate potentiated the vasoconstrictor effect of ANG I1 on preglomerular vessels but did not substantially alter the constrictor action of ANG I1 on postglomerular vessels.
In normal filtering kidneys with intact PG synthesis and servo-controlled renal artery perfusion pres- The inability of ANG 11, at physiological concentrations, to directly increase preglomerular resistance is apparently not due to a lack of receptors on preglomerular vessels. After meclofenamate treatment, ANG I1 caused marked increases in preglomerular resistance in normal as well as in non-filtering kidneys in which changes in renal perfusion pressure and tubuloglomerular feedback were blocked. This observation supports the concept that renal PG may play an important role in minimizing ANG I1 constriction of preglomerular vessels. However, meclofenamate did not appear to markedly alter the response of efferent arterioles to ANG 11, suggesting that the protective effect of PG is selective and confined mainly to preglomerular vessels. This protective effect of PG may also explain why ANG I1 is ineffective in constricting isolated afferent arterioles and intralobular arteries [ l l ] in which the ability to synthesize PG is presumably still intact.
The selective effect of renal PG to protect preglomerular vessels from ANG I1 constriction may be important in allowing the renin-angiotensin system to act as an effective controller of GFR by preferential constriction of efferent arterioles. Previous studies have demonstrated that during various physiological and pathophysiological conditions, such as low sodium intake [16] To the extent that ANG I1 decreases K,, our calculations would tend to underestimate increases in efferent arteriolar resistance and overestimate increases in preglomerular resistance caused by ANG I1 in normal filtering kidneys. This would tend to bias the results against our hypothesis that ANG I1 normally has no significant effect on preglomerular resistance. However, in non-filtering kidneys, the calculations of renal segmental resistances are independent of K, since GFR is zero. The fact that similar results were obtained in non-filtering and filtering kidneys strengthens our conclusion that PG selectively protect preglomerular vessels from the constrictor effect of ANG II.
Another factor that must be considered in our experiments is that the contribution of renal PG in offsetting the constrictor effect of ANG I1 may have been magnified by the use of captopril to block endogenous ANG I1 formation. Captopril has been shown to increase PG synthesis in rat glomeruli [22] , but the importance of this effect in altering overall renal haemodynamics is still unclear.
It is possible that some other effect of meclofenamate, besides blockade, of PG synthesis, may have altered the constrictor response to ANG I1 in preglomerular vessels. For example, cyclo-oxygenase inhibitors could also decrease phosphodiesterase activity and cause accumulation of adenosine. We have previously shown that when renal adenosine levels are elevated, ANG I1 may have a marked constrictor action on preglomerular vessels as well as on efferent arterioles [23]. Therefore, we cannot completely rule out the possibility that part of the effect of meclofenamate on the renal vascular response to ANG I1 may be due to increased levels of adenosine rather than blockade of PG synthesis. It is also possible that meclofenamate may have some other non-specific action on preglomerular vessels that could alter their response to ANG 11. Also, because meclofenamate blocks the entire PG cascade, it is not possible from the present studies to determine which of the renal PG may be most important in protecting against ANG I1 vasoconstriction of preglomerular vessels. Further studies are needed to determine the exact mechanism by which ANG I1 and PG interact on preglomerular vessels.
In summary, the results from the present study suggest that ANG I1 causes marked increases in efferent arteriolar resistance with little or no direct effect on preglomerular vessels. The small increase in preglomerular resistance that occurred during ANG II infusion in normal kidneys appears to be a secondary autoregulatory response due to increased renal perfusion pressure or changes in tubuloglomerular feedback activity. The lack of a direct effect of ANG I1 on preglomerular vessels is apparently due, in part, to a selective action of renal PG to protect these vessels from ANG 11 constriction. However, renal PG do not appear to interfere with the constrictor effect of ANG I1 on postglomerular vessels. This protective effect of renal PG on preglomerular vessels may play an important role in allowing the renin-angiotensin system to effectively control GFR through an efferent arteriolar mechanism and to prevent the development of a vicious cycle leading to renal failure.
